Mountain Crest Acquisition Corp II

Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. It engages in developing a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. It offers software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate milestones. “Better Therapeutics is poised to enter the next phase of its growth as a commercial company, with the recent completi

Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, August 1

Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.

Why Is Better Therapeutics (BTTX) Stock Up 27% Today?

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the completion of the pivotal clinical trial for BT-001, an investigational first-in-class prescription digital therapeutic that is designed to use nCBT to treat type 2 diabetes (T2D). With the positive data reported by this pi

Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen

Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detailing the study design and methodology for its pivotal clinical trial of BT-001 in adult patients with type 2 diabetes (T2D) in the medical journal, Clinical Cardiology. The study represents a first-in-class random

Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical Cardiology

Gevo

Ocean Power Technologies

While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.

3 Penny Stocks That Have Huge Catalysts Ahead

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m. ET. The live panel will be availa

Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss the recently released promising pivotal clinical trial data for BT-001, its digital therapeutic platform for type 2 dia

Better Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company's digital therapeutics platform, designed to help treat cardiometabolic diseases

Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role un

Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

Eos Energy Enterprises

Redbox Entertainment

This week's list of potential short squeeze stocks from Fintel is certainly drawing attention, with some big names featured on the list. The post Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop

GameStop

Arcimoto

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: Redbox Tops List With Huge Numbers, GameStop Rejoins The Leaderboard Ahead Of Earnings

Aterian

Express

Innoviz Technologies

Top penny stocks to watch in June 2022 The post 5 Top Penny Stocks For Your Watch List In June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks For Your Watch List In June 2022

Invesco Mortgage Capital

Zovio

Why these penny stocks are climbing right now The post Top 3 Penny Stocks Outperforming the Stock Market in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 3 Penny Stocks Outperforming the Stock Market in May 2022

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Kevin Appelbaum – Co-Founder and Chief Executive Officer Mark Berman – Chief Medical Officer Mark Heinen – Chief Financial Officer Conference Call Participants Thomas Flaten – Lake Street Capital Charles Rhyee – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good morning, and welcome to the Better Therapeutics First Quarter 2022 Financial Results and Business Update Conference Call. After the speakers' presentation, there will be a question-and-answer session.

Better Therapeutics' (BTTX) CEO Kevin Appelbaum on Q1 2022 Results - Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate milestones. “Better Therapeutics has made significant progress in advancing the clinical development of its first-in-class digital

Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones

Better Therapeutics is delivering a cognitive behavioural therapy through a smartphone app. It is targeting traditionally biopharma diseases like diabetes and other cardiometabolic diseases.

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

Ambev

IAMGOLD

Check these three penny stocks out for your stock market crash watchlist The post Penny Stocks to Buy Right Now? 3 to Watch as the Stock Market Falls appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy Right Now? 3 to Watch as the Stock Market Falls

Sharps Technology Inc

Check these tips out for trading penny stocks in 2022 The post What You Need to Know About Buying Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What You Need to Know About Buying Penny Stocks in 2022

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its first quarter 2022 financial results before the market opens on Friday, May 13, 2022. Management will host a conference call and webcast to provide a business update at 8:30 a.m. Eastern Time on Friday, May 13, 2022. The con

Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022

Mind Medicine MindMed

Sunworks

Alaunos Therapeutics

Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks With Huge Potential According To 4 Wall Street Analysts

Better Therapeutics (BTTX) stock is rising higher on heavy trading Monday despite a lack of news from the biotechnology company. The post Why Is Better Therapeutics (BTTX) Stock Up 30% Today?

Why Is Better Therapeutics (BTTX) Stock Up 30% Today?

Luokung Technology Corp

Here's what you need to know about trading penny stocks today The post Best Penny Stocks to Buy Today? 3 to Watch as the Market Drops Again  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Mountain Crest Acquisition Corp II Stock (BTTX)